E. Dee

Identification of potential drug name confusion errors in the Sentinel System

Qoua L. Her, N. Cocoros, S. Toh, 2019, Pharmacoepidemiology and drug safety.

Risk of Psychiatric Adverse Events among Montelukast Users.

Jennifer G. Lyons, N. Cocoros, S. Toh, 2020, The journal of allergy and clinical immunology. In practice.

Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study

B. Cheung, R. Chan, E. Dee, 2022, medRxiv.

Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.

S. Toh, M. Bradley, T. Woodworth, 2021, JNCI cancer spectrum.

Complementary Use of U.S. FDA’s Adverse Event Reporting System and Sentinel System to Characterize Direct Oral Anticoagulants‐Associated Cutaneous Small Vessel Vasculitis

Casie E. Horgan, E. Eworuke, M. Muñoz, 2020, Pharmacotherapy.

Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness

Jennifer G. Lyons, S. Toh, M. Nguyen, 2019, Pharmacoepidemiology and drug safety.

Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

Christian Hampp, Casie E. Horgan, Catherine A. Panozzo, 2019, Diabetes Care.

Temporal Patterns in Chlamydia Repeat Testing in Massachusetts.

Jessica G. Young, John T. Menchaca, Elizabeth A Torrone, 2019, American journal of preventive medicine.